Preliminary evaluation of serial 18fdg-pet/ct to assess response to toceranib phosphate therapy in canine cancer

Veterinary Radiology and Ultrasound

Volumn 53, Issue 3, 2012, Pages 348-357

  Leblanc, Amy K ^a,b,c   Miller, Ashley N ^a   Galyon, Gina D ^a   Moyers, Tamberlyn D ^a   Long, Misty J ^b   Stuckey, Alan C ^b   Wall, Jonathan S ^b   Morandi, Federica ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

^b UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

Author keywords

18FDG; Cancer; Canine; PET CT; Toceranib cancer

Indexed keywords

ANIMALIA; CANIS FAMILIARIS;

ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; INDOLE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRROLE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TOCERANIB;

ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; DRUG ANTAGONISM; NEOPLASM; SCINTISCANNING;

ANIMALS; ANTINEOPLASTIC AGENTS; DOG DISEASES; DOGS; FLUORODEOXYGLUCOSE F18; INDOLES; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PYRROLES; RADIOPHARMACEUTICALS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84865096061     PISSN: 10588183     EISSN: 17408261     Source Type: Journal    
DOI: 10.1111/j.1740-8261.2012.01925.x     Document Type: Article

References (32)

1. London CA, Galli SJ, Yuuki T, Hu Z-Q, Helfand SC, Geissler EN. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 1999;27:689-697.
2. London CA, Malpas PB, Wood-Follis SL, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009;15:3856-3865.
3. London CA. Tyrosine kinase inhibitors in veterinary medicine. Top Companion Anim Med 2009;24:106-112.
4. Downing S, Chien MB, Kass PH, Moore PE London CA. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors in dogs. Am J Vet Res 2002;63:1718-1723.
5. Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, Miller R, Resau JH, Kiupel M. The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia 2006;8:104-111.
6. London CA, Hannah AL, Zoadovoskaya R, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 2003;9:2755-2768.
7. Brown RJ, Newman SJ, Durtschi DC, LeBlanc AK. Expression of PDGFR-β and kit in canine anal sac apocrine gland adenocarcinoma using tissue immunohistochemistry. Vet Comp Oncol August 2011 [epub ahead of print]
8. Mathie T, Stingle N, Clifford C, et al. Preliminary evidence for biologic activity of toceranib phosphate (Palladia) in solid tumors. Vet Comp Oncol [epub ahead of print]; 01 JUN, 2011.
9. Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic PET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006;91:4070-4076.
10. Calvo OF, Vazquez DD, Lopez MR, et al. Renal cell carcinoma: complete response. Anticancer Drugs 2010;21(Suppl 1):S17- S18.
11. Dawson SJ, Conus NM, Toner GC. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer Drugs 2008;19:547-552.
12. Strobel P, Bargou R, Wolff A et al. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer 2010;103(2):196-200.
13. Jhiang SM. The RET proto-oncogene in human cancers. Oncogene 2000;19:5590-5597.
14. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Radiotherapy and Radiopharmaceuticals 2009;24:137-144.
15. LeBlanc AK, Wall JS, Morandi F, et al. Normal thoracic and abdominal distribution of 2-deoxy-2-[18F]fluoro-D-glucose in adult cats. Vet Radiol Ultrasound 2009;50:435-440.
16. LeBlanc AK, Jakoby BW, Townsend DW, Daniel GB. PET imaging in canine lymphoma and cutaneous mast cell tumor. Vet Radiol Ultrasound 2009;50:215-223.
17. 18FDG) with positron emission tomography in the normal dog. Vet Radiol Ultrasound 2008;49:182-188.
18. Lawrence J, Rohren E, Provenzale J. PET/CT today and tomorrow in veterinary cancer diagnosis and monitoring: fundamentals, early results, and future perspectives. Vet Comp Oncol 2010;8:163-187.
19. Hansen AE, McEvoy F, Engelholm SA, Law I, Kristensen AT. FDG PET/CT imaging in canine cancer patients. Vet Radiol Ultrasound 2011;52:201-206.
20. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50:122S-150S.
21. Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE). Following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:194-213.
22. Lois C, Jakoby BW, Long MJ et al. An assessment of the impact of incorporating time-of-flight information into clinical PET/CT imaging. J Nucl Med 2010;51:237-245.
23. Wilkins DK, Nathan PD. Therapeutic opportunities in noncutaneous melanoma. Therapeutic advances in medical oncology. Ther Adv Med Oncol 2009;1:29-36.
24. Shanbhogue AK, Karnad AB, Prasad SR. Tumor response evaluation in oncology: current update. J Comput Assist Tomogr 2010;34:479-484.
25. Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA Effects of noise, image resolution, and ROI definition on the accuracy of standardized uptake values: a simulation study. J Nucl Med 2004;45:1519-1527.
26. Benjamin RS, Choi H, Macapinlac HA, et al. We should decist using RECIST, at least in GIST. J Clin Oncol 2007;25:1760-1764.
27. Van den Abbeele AD. The lessons of GIST: PET and PET/CT - a new paradigm for imaging. Oncologist 2008; 13(suppl 2): 8-13.
28. Yoon SY, Kim SY, Cho YH, Chung HW, So Y, Lee HM. Hepatic metastases of gastric adenocarcinoma showing metabolic remission on FDG-PET despite an increase in size on CT. Cancer Res Treat 2009;41:100-103.
29. Antoch G, Kanja J, Bauer S, Kuehl H, et al. Comparison or PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004;45:357-365.
30. Goerres GW, Stupp R, Bargouth, G et al. The value of PET, CT, and in-line PET/CT in patients with gastrointestinal stromal tumors: long-term outcome of treatment with imatinib meslylate. Eur J Nucl Med Mol Imaging 2005;32:153-162.
31. Langenbach A, McManus PM, Hendrick MJ, et al. Sensitivity and specificity of methods assessing the regional lymph nodes for evidence of metastasis in dogs and cats with solid tumors. J Am Vet Med Assoc 2001;218:1424-1428.
32. Williams LE, Packer LA. Association between lymph node size and metastasis in dogs with oral malignant melanoma: 100 cases (1987-2001). J Am Vet Med Assoc 2003;222:1234-1236.